"$2B / 5 equals avg of 400M per year. Apply that with a PE of 10 gives a market cap 4B."
That is indeed one conservative PE ratio - the average for the biotech industry on the ASX is 46 which on the 'lower side' of that average is CSL with a PE of 37, so that's your conservative base case. For contrast, Telix has a PE of 124. Pretty much pick any number well north of 50 for the PE for any ASX biotech that gets their first drug to market.
Ann: Security Class Reinstatement to Quotation- OPTOB, page-210
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.0¢ |
Change
0.035(4.00%) |
Mkt cap ! $1.120B | |||
| Open | High | Low | Value | Volume |
| 90.0¢ | 94.0¢ | 87.5¢ | $6.570M | 7.220M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29000 | 90.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 20922 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |